ライフサイエンスコーパス: absolute neutrophil count

1 before transplantation, and having a higher absolute neutrophil count.

2 count (WBC), including a 10-fold rise in the absolute neutrophil count.

3 lgrastim caused a dose-dependent increase in absolute neutrophil count.

4 Lesser value was placed on alterations in absolute neutrophil counts.

5 haemoglobin concentration 9 g/dL or higher, absolute neutrophil count 1 x 10(3) cells per mm(3) or h

6 ed as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet cou

7 roup vs 21 [16%] in the CRT only group), low absolute neutrophil count (15 [12%] vs 24 [19%]), fatigu

8 s for white blood cell count (11600/microL), absolute neutrophil count (4100/microL), and platelet co

9 All patients engrafted to an absolute neutrophil count 500/microL at a median of 13 d

10 wing transplantation, the median times to an absolute neutrophil count (ANC) > 0.5 x 10(9)/L were 12,

11 The median time to reach an absolute neutrophil count (ANC) > or = 500/microL in the

12 The median time to achieve an absolute neutrophil count (ANC) > or = 500/microL was 13

13 idered together, the median time to reach an absolute neutrophil count (ANC) > or = 500/microL was 18

14 endent by day 23 posttransplant and achieved absolute neutrophil count (ANC) >500/microL by day 25 +/

15 ge, 18 to 63), and the median duration of an absolute neutrophil count (ANC) < or = 500/microL and pl

16 MK-7123 caused a dose-dependent decrease in absolute neutrophil count (ANC) and reduced inflammatory

17 The median absolute neutrophil count (ANC) at diagnosis was 0.4 x 1

18 out baseline neutropenia, 82% of those whose absolute neutrophil count (ANC) decreased by > or = 75%

19 The median time to reach an absolute neutrophil count (ANC) greater than 500/microl

20 ollowing autologous PBSC transplant, with an absolute neutrophil count (ANC) greater than 500/microL

21 or (GCSF) has been used to increase systemic absolute neutrophil count (ANC) in patients with severe

22 kinetics of the CD34+ cell mobilization, the absolute neutrophil count (ANC) increased markedly by 6

23 omponents resulted in significant, sustained absolute neutrophil count (ANC) increments.

24 mong patients alive on any given day with an absolute neutrophil count (ANC) less than 100/microL com

25 significant difference in number of days of absolute neutrophil count (ANC) less than 500/microL, ho

26 ed fifteen consecutive episodes of fever and absolute neutrophil count (ANC) less than 500/microliter

27 s delay in therapy for inadequate counts: an absolute neutrophil count (ANC) more than 1,000/microL a

28 The mean time to absolute neutrophil count (ANC) more than 500/mm(3) was

29 Univariate and multivariate models of absolute neutrophil count (ANC) nadir and pharmacokineti

30 nsplant (p.t.) in a stable condition with an absolute neutrophil count (ANC) of 2,700 cells per micro

31 owing criteria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/m

32 patients required bone marrow reinfusion for absolute neutrophil count (ANC) of less than 200/microL

33 rog/kg/d), but achieved less than the median absolute neutrophil count (ANC) response (ANC < 2.188 x

34 ceived filgrastim (5 mcg/kg) daily until the absolute neutrophil count (ANC) was > or = 1,500 microL

35 on day 2 and continuing until the post-nadir absolute neutrophil count (ANC) was > or = 10,000/microL

36 after the completion of cladribine until the absolute neutrophil count (ANC) was >/=2 x 10(9)/L on 2

37 Median time to recovery of absolute neutrophil count (ANC) was 12 days.

38 prophylactic ciprofloxacin by mouth when the absolute neutrophil count (ANC) was less than 1,000/micr

39 Absolute neutrophil count (ANC) was summarized as mean A

40 ow cells were substantially reduced, and the absolute neutrophil counts (ANC) and expression of bcl-x

41 In this cohort, 159 patients (57%) had absolute neutrophil counts (ANC) less than 1,500/microL,

42 rhG-CSF resulted in a slight increase in absolute neutrophil counts (ANC), but did not provide a

43 e to the commercial G-CSF on the increase of absolute neutrophil counts (ANC).

44 2 of each cycle through neutrophil recovery (absolute neutrophil count [ANC] > 10,000/microL).

45 ngrafted successfully, although granulocyte (absolute neutrophil count [ANC] >0.5 x 10(9)/L, 16 days)

46 All patients developed grade 4 neutropenia (absolute neutrophil count [ANC] < 500 microL), generally

47 The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and mil

48 tion and the durations of neutropenia (NEUT; absolute neutrophil count [ANC] < 500/microL) and thromb

49 y reduced the mean durations of neutropenia (absolute neutrophil count [ANC] < 500/microL) and thromb

50 r more of the following events: neutropenia (absolute neutrophil count [ANC] < or = 250/microL), dose

51 d 9 had a single lineage response (8 of 9 in absolute neutrophil count [ANC] and 1 had more than a 50

52 defined by a predictive model based on nadir absolute neutrophil count [ANC] and hemoglobin decrease

53 n BM and blood with normalization of counts (absolute neutrophil count [ANC]> 1.5 x 10(9)/L, hemoglob

54 nd inflammation (alkaline phosphatase [ALP], absolute neutrophil count [ANC], ferritin [adjusted for

55 g/d on days 3 to 18 or until two consecutive absolute neutrophil counts (ANCs) > or = 10,000/microL w

56 s poor correlation between the WBC count and absolute neutrophil counts (ANCs) and both the area unde

57 Prechemotherapy median absolute neutrophil counts (ANCs) in patients receiving

58 Peripheral blood absolute neutrophil count and G-CSF levels were determin

59 rated and to induce significant increases in absolute neutrophil count and NSP.

60 the accuracy of the white blood cell count, absolute neutrophil count, and platelet count at commonl

61 macodynamic relationship between Tss and the absolute neutrophil count at the nadir (ANCn) was descri

62 e adjusted 20% each cycle to achieve a nadir absolute neutrophil count below 0.5 x 10(9)/L.

63 ile neutropenia, lung infection with grade 4 absolute neutrophil count, colon infection with grade 4

64 beyond a standard white blood cell count or absolute neutrophil count, continue to be investigated,

65 The percentage drop in absolute neutrophil count correlates with the area under

66 Median absolute neutrophil count decrease was 26%, and platelet

67 ht, brain and body temperature, and systemic absolute neutrophil counts did not differ between groups

68 If the absolute neutrophil count dropped below 1000, the dose w

69 Chronic neutropenia is defined as a low absolute neutrophil count for >6 months.

70 ependently predictive of time to recovery of absolute neutrophil count for both the fourth and fifth

71 utrophil count, colon infection with grade 4 absolute neutrophil count, grade 4 changed mental status

72 ined as independence from transfusion and an absolute neutrophil count greater than 0.5 x 10(9) cells

73 The median time to achieve an absolute neutrophil count greater than 0.5 x 10(9)/L was

74 Mean time to engraftment of an absolute neutrophil count greater than 500/microL (0.5 x

75 The median times to reach an absolute neutrophil count greater than 500/microL and pl

76 ry 21 and 14 days, respectively, provided an absolute neutrophil count greater than 750x10(6)/L and a

77 primary graft failure (failure to achieve an absolute neutrophil count > 5 x 10(8)/L before death or

78 The median time to engraftment (absolute neutrophil count > 500/mm(3) and platelets 50 0

79 have adequate hepatic and renal function, an absolute neutrophil count > or = 500/microL and a platel

80 aftment of all cell lineages: median time to absolute neutrophil count > or = 500/microL, 10 days ver

81 supported the extended use of CSFs until an absolute neutrophil count >/= 10,000/mm(3) or a WBC coun

82 t >/=15000/microL, 27% (95% CI, 18% to 36%); absolute neutrophil count >/=10000/microL, 18% (95% CI,

83 ias was slower after CPX-351 (median days to absolute neutrophil count >/=1000: 36 vs 32; platelets >

84 tpatients as defined by neutrocytic ascites (absolute neutrophil count >or=250 cells/mm(3)) was 3.5%.

85 The eight patients have recovered absolute neutrophil counts > 500/microL on a median of 8

86 plete response (hemoglobin level, > 13 g/dL; absolute neutrophil count, > 1.5 x 10(9)/L, and platelet

87 These patients engrafted neutrophils (absolute neutrophil count, >500/microL) in a median of 6

88 Median time to an absolute neutrophil count higher than 0.5x10(9)/L and no

89 IL-3 significantly increased the absolute neutrophil count in seven patients (87%) but ha

90 y inflammation, including total cell counts, absolute neutrophil counts, interleukin-8 (IL-8) levels,

91 with the two cytokines, the duration of the absolute neutrophil count less than 1,000/muL for all cy

92 /- 20 x 10(9)/L on day 17), and neutropenia (absolute neutrophil count < 1 x 10(9)/L) occurred betwee

93 rradiation and the durations of neutropenia (absolute neutrophil count < 500/microL) and thrombocytop

94 f torsade de pointes and severe neutropenia (absolute neutrophil count < or =500 cells/microL) were s

95 n-chemotherapy drug-induced agranulocytosis (absolute neutrophil count </=0.5 x 10(9)/L [</=500/muL])

96 ified patients with concomitant neutropenia (absolute neutrophil count <1000 cells/microL) and abdomi

97 igible subjects were those with neutropenia (absolute neutrophil count <500/muL) and proven/probable/

98 imab, and 7 days from prior corticosteroids; absolute neutrophil count more than 1,500/microL (500/mi

99 The median time to absolute neutrophil count more than 500/microL after ASC

100 Absolute neutrophil counts, motor function, Morris water

101 ed mice had a rapid though transient rise in absolute neutrophil counts, mTNF-alpha, mIL-1beta, mIL-6

102 notype was significantly associated with the absolute neutrophil count nadir (7/7 < 6/7 < 6/6, P =.02

103 lted in an elevated HbF without neutropenia (absolute neutrophil count nadir greater than 1500) or ev

104 The time to the absolute neutrophil count nadir was shorter for the (90)

105 time curve were significant predictors of ln(absolute neutrophil count nadir; r(2) = 0.51).

106 in cohort 3 experienced significantly lower absolute neutrophil count nadirs than did younger groups

107 se mice, significant increases were noted in absolute neutrophil count nadirs, reticulocyte indices,

108 The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (ran

109 The median time to an absolute neutrophil count of 0.5 x 10(9) cells/L was 49

110 eceived filgrastim had faster recovery of an absolute neutrophil count of 0.5 x 10(9)/L or greater (a

111 e was discharged in stable condition with an absolute neutrophil count of 100 cells per microliter.

112 An absolute neutrophil count of 500 x 10(6)/L was achieved

113 The median time to reach an absolute neutrophil count of 500/microL or greater was 1

114 An absolute neutrophil count of 500/microL was achieved on

115 ary LR, 0.22; 95% CI, 0.17-0.30), as does an absolute neutrophil count of 6750/microL or lower (LR, 0

116 The median time to an absolute neutrophil count of at least 500 per cubic mill

117 penia was not significantly different at the absolute neutrophil count of less than 0.5 x 109 cells/L

118 ree patients treated with tofacitinib had an absolute neutrophil count of less than 1500.

119 n the absence of enzyme replacement therapy, absolute neutrophil counts of patients with ADA deficien

120 eriencing an 84% decrease in the circulating absolute neutrophil count (P<0.001) before elastase perf

121 tive protein concentration (p=0.0003) and in absolute neutrophil count (p=0.024) at 24 h after treatm

122 ores correlated inversely with leukocyte and absolute neutrophil counts (P <.01) and correlated direc

123 nt relationship between TAS-103 AUC and D 15 absolute neutrophil count (r = -0.63, P <.05, n = 11, on

124 nts received 10 microg/kg/d filgrastim until absolute neutrophil count recovery.

125 End points included increase in absolute neutrophil count, safety of filgrastim, and fre

126 The median time to recovery of absolute neutrophil count to >/= 500 cells/microL was 11

127 neutropenic patients as 100% increase in the absolute neutrophil count to more than 5 x 10(8) cells p

128 mal mice with antineutrophil serum to reduce absolute neutrophil counts to < 100 cells/mm3.

129 Treatment was repeated every 2 weeks if the absolute neutrophil count was > or = 750/microL and plat

130 00 microg [n = 20]) for 10 days or until the absolute neutrophil count was >75,000 cells/mm3 or until

131 The median presenting absolute neutrophil count was 100/muL.

132 Compared with control, systemic absolute neutrophil count was increased more than ten-fo

133 colony-stimulating factor was used when the absolute neutrophil count was less than 1,000/microL.

134 ive prophylactic oral ciprofloxacin when the absolute neutrophil count was less than 1,000/microL.

135 therapy, one from infection (although their absolute neutrophil count was normal), which was definit

136 In burn sepsis, absolute neutrophil count was reduced whereas plasma G-C

137 en patients had a 50% or greater increase in absolute neutrophil count with amifostine treatment (ran

138 tment led to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38%